Drugdev
Drugdev is recorded as a service provider in 25 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 25 trials · Latest update first
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non–Small Cell Lung Cancer (POD1UM-304)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
A phase IIIb, Multicenter, Single-Arm Study Assessing the Effectiveness, Safety and Patient Reported Outcomes of a 36-week Refill Exchange Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 4, multicenter, prospective, open-label study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythematosus
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
LUMIOS - A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to assess the efficacy, safety and tolerability of cenerimod in adult patients with systemic lupus erythematosus and active lupus nephritis in combination with background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
Phase 3, Open-label, Single-dose, Multicenter Study Investigating Efficacy, Safety, and Tolerability of CSL222 (Etranacogene Dezaparvovec) Administered to Adolescent Male Subjects (≥ 12 to < 18 Years of Age) with Severe or Moderately Severe Hemophilia B
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB 3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Sponsor BeOne Medicines AG
- Start (EU)
- Latest update
- Estimated end
INCMGA 0012-303: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)
Sponsor Incyte Corp.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available5 trial-level findings · Read insights
- The study randomized 308 participants at 70 centers in Australia, Belgium, Denmark, France, Germany, Italy, Japan, Norway, Puerto Rico, Spain, Sweden, the United Kingdom, and the United States.
- Enrollment was concentrated in France (102 participants), the United Kingdom (56), Italy (48), and Spain (31), while each other reporting country enrolled 2-19 participants.
- A December 2021 global protocol amendment removed interim analyses and clarified eligibility criteria.
- A May 2022 global protocol amendment updated eligibility criteria for Japanese participants.
- A February 2025 global protocol amendment updated the frequency of imaging during the disease follow-up phase.
These findings describe the trial, not the service provider’s performance or responsibility.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk
Sponsor Exelixis Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase IIIb, Global, Multicenter, Randomized, Visual Assessor−Masked Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration (Velodrome)
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
Sponsor Karyopharm Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dosefinding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder
Sponsor Idorsia Pharmaceuticals Ltd.
- Start (EU)
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled, Dose Range Finding Study to Evaluate the Efficacy, Safety, and Tolerability of Nebulized CSL787 in Adults (18 to 85 years) with Non-cystic Fibrosis Bronchiectasis
Sponsor CSL Behring LLC
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Sponsor Tesaro Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo® Versus Placebo in Combination with Phesgo® as Maintenance Therapy After First Line Induction Therapy in Participants with PIK3CA‑Mutated HER2‑Positive Locally Advanced or Metastatic Breast Cancer
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Choroidal Neovascularization Secondary to Pathologic Myopia
Sponsor F. Hoffmann-La Roche AG
- Start (EU)
- Latest update
- Estimated end
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care
Sponsor Biogen Idec Research Limited
- Start (EU)
- Latest update
- Estimated end
An Open-label Study to Evaluate the Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema
Sponsor CSL Behring LLC
- Start (EU)
- Latest update
- Estimated end
OPUS-1 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy
Sponsor Viatris Innovation GmbH
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Drugdev?
The 2026-10-09 snapshot links Drugdev to 25 distinct CTIS trials. Recorded services include Payment services, Investigator Portal, Site Start-up Management, Project & Vendor management, Medical Monitoring & 24hr Emergency, contact, Electronic consent, among 12 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Drugdev?
The most frequently recorded therapeutic areas are Immunology, Solid Tumor Oncology, Haematological Malignancies, Ophthalmology. Recorded phases include Phase 3, Phase 2, Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Drugdev conducted?
The linked trials record locations in 19 countries, including Spain, Germany, Italy, France, Poland. These are trial locations, not confirmed office locations or countries where Drugdev delivered services.
What can this page tell me about Drugdev's trial experience?
Browse 25 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 2 recorded name variants under Drugdev. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- DrugDev Inc.
- Drugdev Inc.